Successful experience with inclisiran in renal transplant patients
https://doi.org/10.23873/2074-0506-2026-18-1-91-100
Abstract
Background. Kidney transplant (KT) recipients are a high-risk group for atherosclerotic cardiovascular disease (CVD), closely linked to dyslipidemia.
Objective. To demonstrate the efficacy and safety of a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, inclisiran, for hyperlipidemia correction in and reduction of the risk of developing CVD in KT recipients.
Material and methods. A series of clinical cases included five patients (two men, three women, mean age 56±10 years) with high cardiovascular risk, dyslipidemia, and persistently elevated low-density lipoprotein (LDL) levels, despite ongoing statin and ezetimibe therapy. Inclisiran targeted therapy was prescribed for secondary (4 patients) and primary (1 patient) CVD prevention. Subcutaneous inclisiran injection (284 mg in 1.5 mL solution) was administered in KT department, repeat injection was made after three months, the next injections were performed after 6 months. Dynamic studies of blood LDL, creatinine, tacrolimus levels were performed using standard methods.
Results. Adjunctive inclisiran therapy led to a reduction in blood LDL levels by an average of 32% at two weeks, 40% at one month, and 55% at three months. Continued treatment maintained target LDL values. Inclisiran treatment caused no adverse effects and had no negative impact on transplanted kidney function.
Conclusion. KT recipients with high risk of atherosclerotic CVD represent a promising group for lipid-lowering therapy including inclisiran.
About the Authors
R. O. Kantaria
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Rusudana O. Kantaria, Cand. Sci. (Med.), Nephrologist of Kidney Transplantation Department, Associate Professor of the Department of Transplantology, Nephrology and Artificial Organs in Faculty of Postgraduate Medical State Institution
61/2 Shchepkin St., Moscow 129110
O. S. Vetchinnikova
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Olga N. Vetchinnikova, Assoc. Prof., Dr. Sci. (Med.), Senior Research Associate of Kidney Transplantation Department, professor of Chair of Therapy in Faculty of Postgraduate Medical State Institution
61/2 Shchepkin St., Moscow 129110
Ya. G. Moysyuk
Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Yan G. Moysyuk, Prof., Dr. Sci. (Med.), Head of the Department of Surgery and Liver Transplantation
61/2 Shchepkin St., Moscow 129110
D. V. Khokhlov
Pushkin Clinical Hospital n.a. prof. Rozanov V.N.
Russian Federation
Russian Federation
Denis V. Khokhlov, Nephrologist, 1st Therapeutic Department
35 Aviatsionnaya St., Pushkino, 141206
References
1. Boenink R, Bonthuis M, Boerstra BA, Astley ME, Montez de Sousa IR, Helve J, et al. The ERA Registry Annual Report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons. Clin Kidney J. 2024;18(2):sfae405. PMID: 40008269 https://doi.org/10.1093/ckj/sfae405
2. Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, et al. Trends in the causes of death among kidney transplant recipients in the United States (1996–2014). Am J Nephrol. 2018;48(6):472–481. PMID: 30472701 https://doi.org/10.1159/000495081
3. Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019;34(5):760–773. PMID: 30984976 https://doi.org/10.1093/ndt/gfz053
4. Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–2330. PMID: 32052833 https://doi.org/10.1093/eurheartj/ehz962
5. Thölking G, Schulte C, Jehn U, Schütte-Nütgen K, Pavenstädt H, Suwelack B, et al. The tacrolimus metabolism rate and dyslipidemia after kidney transplantation. J Clin Med. 2021;10(14):3066. PMID: 34300232 https://doi.org/10.3390/jcm10143066
6. Agarwal A, Prasad GVR. Posttransplant dyslipidemia: mechanisms, diagnosis and management. World J. Transplant. 2016;6(1):125–134. PMID: 27011910 https://doi.org/10.5500/wjt.v6.i1.125
7. Kurdi A, MartinetW, Meyer GRY. mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation. 2018;102(2SSuppl 1):S44-S46. PMID: 28230638 https://doi.org/10.1097/TP.0000000000001693
8. Barbagallo CM, Cefalù AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, et al. Lipoprotein abnormalities in chronic kidney disease and renal transplantation. Life. 2021;11(4):315. PMID: 33916487 https://doi.org/10.3390/life11040315
9. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014;2014(1):CD005019. PMID: 24470059 https://doi.org/10.1002/14651858.CD005019
10. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. PMID: 34458905 https://doi.org/10.1093/eurheartj/ehab484
11. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm JR, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4Suppl 7:13–53. PMID: 15027968 https://doi.org/10.1111/j.1600-6135.2004.0355.x
12. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182–1193. PMID: 33663735 https://doi.org/10.1016/j.jacc.2020.12.058
13. ЗZyryanov SK, Butranova OI. New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. Russian Journal of Cardiology. 2022;27(11):52–71. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5271
14. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530. PMID: 32197277 https://doi.org/10.1056/NEJMoa1913805
15. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. ORION10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. PMID: 32187462 https://doi.org/10.1056/NEJ-Moa1912387
16. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69–73. PMID: 32892993 https://doi.org/10.1016/j.amjcard.2020.08.018
17. Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiteret LA, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129–138. PMID: 36331326 https://doi.org/10.1093/eurheartj/ehac594
18. Medvedeva EA, Grigorenko EA, Mitkovskaya NP. Innovative lipidlowering therapy: experience of inclisiran use in the Republic of Belarus. Russian Journal of Cardiology. 2023;28(4):54–61. (In Russ.). https://doi.org/10.15829/15604071-2023-5417
19. Tatarintseva ZG, Tkhatl LK, Barbuhatti KO, Kosmacheva ED. A case of successful treatment of severe hyperlipidemia after heart transplantation with inclisiran. Kardiologiia. 2024;64(7):72–76. (In Russ.). https://doi.org/10.18087/cardio.2024.7.n2679
20. Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K, Reuter S. Novel therapeutic strategies for dyslipidemia: first report of inclisiran therapy in a kidney transplanted patient. Transpl Int. 2023;36:11104. PMID: 36776901 https://doi.org/10.3389/ti.2023.11104
21. Kordonova OO, Gubarev KK, Frolova NF, Svetlakova DS, Voskanyan SE, Artyukhina LYu. Treatment of dyslipidemia using inclisiran in a case series of patients after kidney and liver transplantation. Clinical nephrology. 2024;2:13–23. (In Russ.). https://doi.org/10.18565/nephrology.2024.2.13-23
22. Cegla G, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, et al. HEART UK consensus statement on Lipoprotein(a). Atherosclerosis. 2019;291:62–70. PMID: 31704552 https://doi.org/10.1016/j.atherosclerosis.2019.10.011
23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314. PMID: 38490803 https://doi.org/10.1016/j.kint.2023.10.018
24. Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmess U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Clinical trial. Mayo Clin Proc. 2020;95(1):77–89. PMID: 31630870 https://doi.org/10.1016/j.mayocp.2019.08.021
Review
For citations:
Kantaria R.O., Vetchinnikova O.S., Moysyuk Ya.G., Khokhlov D.V. Successful experience with inclisiran in renal transplant patients. Transplantologiya. The Russian Journal of Transplantation. 2026;18(1):91-100. (In Russ.) https://doi.org/10.23873/2074-0506-2026-18-1-91-100
Views:
230
JATS XML
Email this article 
